SAN MARINO, Calif., June 8, 2011 /PRNewswire/ -- VG Energy, Inc., a majority-owned subsidiary of Viral Genetics, Inc. (Pinksheets: VRAL), has received independent confirmation from BioProcess Algae, LLC of early laboratory studies that verify an increase in yields of algae oils following treatment with VG Energy's Metabolic Disruption Technology (MDT) additives. These test studies hold promise for the use of VG's proprietary technology in the large-scale commercial production of biofuels as well as high-value oils used in cosmetics, food and nutraceuticals, among other products.
"We are pleased but not surprised by these early results," said Viral Genetics CEO Haig Keledjian. "Seeing these positive results has been the confirmation that was needed to go forward with the next phase of this particular study."
The results represent the completion of the first two steps of a viability study that VG Energy retained BioProcess Algae to conduct, originally announced on March 25, 2011. BioProcess Algae initially performed a Feasibility Assessment Study to establish baseline performance of VG's technology, with algal strains provided by VG and additional strains from BioProcess Algae. Recognizing an increase in Mean Nile Red Fluorescence, with the strongest effects seen after 48 hours, the study verifies bench-level results of VG's lipid enhancement technology. The next step will be a Dosage Response Study followed by testing at industrial-scale studies.
The Dosage Response Study, expected to be completed within a month, will determine the optimal dosage for the highest lipid outcome in the plant strains selected, according to Dr. M. Karen Newell Rogers, VG Energy's head of scientific research. "It is important that we are thorough in our studies, dosage and selection in order to continuously move the bar to get the highest yields possible," noted Dr. Newell Rogers.
"Although we've seen these results now internally multiple times, it was impor
|SOURCE VG Energy, Inc.|
Copyright©2010 PR Newswire.
All rights reserved